Loading...
•
Jan 31, 2022
KalVista Q3 2022 Earnings Report
KalVista reported third fiscal quarter results with KVD900 Phase 3 KONFIDENT trial initiated and KVD824 Phase 2 KOMPLETE clinical trial enrollment on track.
Key Takeaways
KalVista Pharmaceuticals reported no revenue for the third fiscal quarter ended January 31, 2022. The net loss was $22.5 million, or $(0.92) per share. Research and development expenses were $19.7 million, and general and administrative expenses were $6.9 million. Cash, cash equivalents, and marketable securities totaled $194.8 million as of January 31, 2022.
Initiated the Phase 3 clinical trial of KVD900 (KONFIDENT) for on-demand treatment of HAE attacks.
Continued enrollment in the Phase 2 clinical trial of KVD824 (KOMPLETE) for HAE prophylaxis, with data expected in mid-2023.
Presented data for KVD900 at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Scientific Meeting.
Made continued progress in the Factor XIIa inhibitor program, with an expected first IND for an oral Factor XIIa inhibitor candidate in 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...